Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT03438344 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Withdrawal

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Bone Marrow Transplantation Recipient
Chronic Lymphocytic Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic Cell Transplantation Recipient
Hodgkin Lymphoma
Myelodysplastic Syndrome
Myelofibrosis
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo

Sponsor

City of Hope Medical Center